{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:18:13Z","timestamp":1783387093359,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejso.2025.109603","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T15:00:51Z","timestamp":1736953251000},"page":"109603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: A single-arm, multicenter phase II clinical trial"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7790","authenticated-orcid":false,"given":"Won Jun","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2567-5533","authenticated-orcid":false,"given":"Chang Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Seob","family":"Jee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Chul","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejso.2025.109603_bib1","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.ejso.2025.109603_bib2","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ejso.2025.109603_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5230\/jgc.2023.23.e11","article-title":"Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach","volume":"23","author":"Kim","year":"2023","journal-title":"J Gastric Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.109603_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2025.109603_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.6004\/jnccn.2013.0070","article-title":"Gastric cancer, version 2.2022","volume":"11","author":"Ajani","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.ejso.2025.109603_bib6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the management of peritoneal malignancies","volume":"19","author":"Kepenekian","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.109603_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ags3.12060","article-title":"Treatment of patients with peritoneal metastases from gastric cancer","volume":"2","author":"Kitayama","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"issue":"S1","key":"10.1016\/j.ejso.2025.109603_bib8","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.109603_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","article-title":"Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration","volume":"155","author":"Soma","year":"2009","journal-title":"J Surg Res"},{"issue":"2","key":"10.1016\/j.ejso.2025.109603_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/pp-2017-0002","article-title":"Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model","volume":"2","author":"Kitayama","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"10.1016\/j.ejso.2025.109603_bib11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5230\/jgc.2021.21.e38","article-title":"Intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasis: a phase I study","volume":"21","author":"Kim","year":"2021","journal-title":"J Gastric Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2025.109603_bib12","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","article-title":"Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis","volume":"29","author":"Kang","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2025.109603_bib13","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2025.109603_bib14","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1245\/s10434-022-11998-z","article-title":"Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases","volume":"29","author":"Chia","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.109603_bib15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fon-2021-1414","article-title":"A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"18","author":"Lu","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2025.109603_bib16","series-title":"Peritoneal carcinomatosis: Principles of management. Vol 82. Cancer treatment and research","first-page":"359","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","author":"Jacquet","year":"1996"},{"issue":"3","key":"10.1016\/j.ejso.2025.109603_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in Solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejso.2025.109603_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00280-011-1561-8","article-title":"A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models","volume":"68","author":"Koo","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ejso.2025.109603_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1010662413174","article-title":"Determinants of paclitaxel uptake, accumulation and retention in Solid tumors","volume":"19","author":"Jang","year":"2001","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1016\/j.ejso.2025.109603_bib21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1535-7163.MCT-21-0750","article-title":"Sustained supratherapeutic paclitaxel delivery enhances irreversible sarcoma cell death","volume":"21","author":"Blessing","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ejso.2025.109603_bib22","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41571-022-00675-5","article-title":"Advances in the management of peritoneal malignancies","volume":"19","author":"K\u00e9p\u00e9n\u00e9kian","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.109603_bib23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/RLU.0000000000002028","article-title":"Should 18F-FDG PET\/CT Be routinely performed in the clinical staging of locally advanced gastric adenocarcinoma?","volume":"43","author":"Perlaza","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"13","key":"10.1016\/j.ejso.2025.109603_bib24","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.3390\/cancers15133425","article-title":"The role of staging laparoscopy for gastric cancer patients: current evidence and future perspectives","volume":"15","author":"Schena","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejso.2025.109603_bib25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1245\/s10434-014-4082-y","article-title":"Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination","volume":"22","author":"Emoto","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T14:47:26Z","timestamp":1753973246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0748798325000319"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109603","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal paclitaxel with systemic S-1 plus oxaliplatin for advanced or recurrent gastric cancer with peritoneal metastasis: A single-arm, multicenter phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.109603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109603"}}